Date: 2018-10-02

Type of information: Licensing agreement

Compound: neoantigen-reactive T cell receptors (TCRs) for the treatment of various cancers

Company: Kite Pharma (USA - CA), a Gilead company (USA - CA) HiFiBiO Therapeutics (USA - MA)

Therapeutic area: Cancer - Oncology

Type agreement: research - licensing

Action mechanism: immunotherapy product/cell therapy



  • • On October 2, 2018, Kite, a Gilead Company, and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
  • Kite and HiFiBiO intend to adapt HiFiBiO's proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies. Neoantigens arise from tumor-specific mutations that are unique to each patient's cancer, offering the potential for more targeted antitumor activity.

Financial terms:

  • Under the terms of the agreement, HiFiBiO will receive a $10 million upfront payment and will be eligible for additional payments based on the achievement of certain research milestones. Kite will have an exclusive option to license HiFiBiO's platform to screen T cell repertoires and to identify TCRs for use in TCR engineered T cell therapies with a corresponding payment to HiFiBiO.

Latest news:

Is general: Yes